MY187045A - Antibodies to tigit - Google Patents
Antibodies to tigitInfo
- Publication number
- MY187045A MY187045A MYPI2017702296A MYPI2017702296A MY187045A MY 187045 A MY187045 A MY 187045A MY PI2017702296 A MYPI2017702296 A MY PI2017702296A MY PI2017702296 A MYPI2017702296 A MY PI2017702296A MY 187045 A MY187045 A MY 187045A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibodies
- fragments
- heavy
- cells
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096267P | 2014-12-23 | 2014-12-23 | |
| PCT/US2015/067332 WO2016106302A1 (en) | 2014-12-23 | 2015-12-22 | Antibodies to tigit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY187045A true MY187045A (en) | 2021-08-27 |
Family
ID=55168435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017702296A MY187045A (en) | 2014-12-23 | 2015-12-22 | Antibodies to tigit |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10189902B2 (enExample) |
| EP (2) | EP4249066A3 (enExample) |
| JP (6) | JP6180663B2 (enExample) |
| KR (1) | KR102644115B1 (enExample) |
| CN (3) | CN107207594B (enExample) |
| AR (1) | AR103268A1 (enExample) |
| AU (2) | AU2015369683C1 (enExample) |
| BR (1) | BR112017013385A2 (enExample) |
| CL (1) | CL2017001660A1 (enExample) |
| CO (1) | CO2017006989A2 (enExample) |
| EA (1) | EA039219B1 (enExample) |
| IL (2) | IL253013B (enExample) |
| MA (1) | MA40662B1 (enExample) |
| MX (2) | MX389267B (enExample) |
| MY (1) | MY187045A (enExample) |
| PE (1) | PE20171244A1 (enExample) |
| PH (2) | PH12022550771A1 (enExample) |
| SG (2) | SG11201705063VA (enExample) |
| TN (1) | TN2017000267A1 (enExample) |
| TW (1) | TWI708786B (enExample) |
| UY (1) | UY36471A (enExample) |
| WO (1) | WO2016106302A1 (enExample) |
| ZA (2) | ZA201704981B (enExample) |
Families Citing this family (199)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| SI3485903T1 (sl) | 2011-09-23 | 2023-02-28 | Mereo Biopharma 5, Inc. | Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CR20170060A (es) | 2014-08-19 | 2017-04-18 | Merck Sharp & Dohme | Anticuerpos anti tigit |
| EP3259597B2 (en) | 2015-02-19 | 2026-04-15 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
| SG11201706583PA (en) | 2015-02-19 | 2017-09-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JP6976241B2 (ja) | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗ｔｉｇｉｔ抗体 |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| UA125062C2 (uk) | 2015-10-01 | 2022-01-05 | Потенза Терапеутікс, Інк. | Анти-tigit антигензв'язуючі білки і способи їх застосування |
| CN116514976A (zh) | 2016-03-04 | 2023-08-01 | Jn生物科学有限责任公司 | 针对tigit的抗体 |
| CN109069638B (zh) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN107698684B (zh) * | 2016-08-03 | 2021-09-28 | 广东东阳光药业有限公司 | 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白 |
| CA3032897A1 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| SG11201901077RA (en) | 2016-08-17 | 2019-03-28 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| CA3044664C (en) * | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
| US10759855B2 (en) * | 2016-12-02 | 2020-09-01 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to TIGIT |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| JP2020510422A (ja) * | 2017-02-28 | 2020-04-09 | シアトル ジェネティックス， インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| EP3595720A4 (en) | 2017-03-14 | 2021-05-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING VISTA AT ACIDIC PH VALUE |
| JOP20190203A1 (ar) * | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| AU2018254626B2 (en) | 2017-04-21 | 2023-12-21 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| EP3615070A1 (en) * | 2017-04-26 | 2020-03-04 | Bristol-Myers Squibb Company | Methods of antibody production that minimize disulfide bond reduction |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| CA3061050A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| US20200299400A1 (en) * | 2017-05-25 | 2020-09-24 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| MX2019014265A (es) * | 2017-06-01 | 2020-08-03 | Compugen Ltd | Tratamientos conjuntos triples con anticuerpos. |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
| BE1025333B1 (fr) * | 2017-07-27 | 2019-01-23 | Iteos Therapeutics S.A. | Anticorps anti-tigit |
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| CN109425736B (zh) * | 2017-08-25 | 2021-04-09 | 北京百普赛斯生物科技股份有限公司 | 一种检测pd-1抗体血药浓度的方法及试剂盒 |
| KR102710422B1 (ko) | 2017-09-07 | 2024-09-25 | 브리스톨-마이어스 스큅 컴퍼니 | 모세관 전기영동에 의한 순도 결정 방법 |
| RU2020112490A (ru) * | 2017-09-13 | 2021-10-13 | Тенеобио, Инк. | Антитела из тяжелых цепей, связывающиеся с эктоферментами |
| US11512129B2 (en) | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| US20190099506A1 (en) | 2017-10-02 | 2019-04-04 | Bristol-Myers Squibb Company | Methods and compositions for deuterated biologics |
| AU2018348093A1 (en) * | 2017-10-10 | 2020-05-28 | Sanofi | Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies |
| KR20200100113A (ko) * | 2017-12-15 | 2020-08-25 | 실버백 테라퓨틱스, 인크. | 간염 치료용 항체 구조물-약물 접합체 |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| TW201930358A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對ｔｉｇｉｔ之單域抗體及其變異體 |
| TWI816729B (zh) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| US11708410B2 (en) | 2018-01-15 | 2023-07-25 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against TIGIT |
| CN110352200B (zh) | 2018-02-06 | 2020-12-11 | 天境生物科技(上海)有限公司 | 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用 |
| MX2020008882A (es) * | 2018-02-26 | 2021-01-08 | Genentech Inc | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. |
| MX2020008795A (es) * | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
| AU2019233576A1 (en) * | 2018-03-13 | 2020-09-17 | Cancer Research Technology Limited | Anti-CD25 for tumour specific cell depletion |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| CA3093407A1 (en) * | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| WO2019190931A1 (en) * | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Anti-pfrh5 antibodies and antigen-binding fragments thereof |
| AU2019248547B2 (en) | 2018-04-02 | 2025-07-17 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
| JP7516254B2 (ja) | 2018-04-18 | 2024-07-16 | ゼンコア インコーポレイテッド | Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用 |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| CA3101019A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| WO2020006516A1 (en) * | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| BR112021001201A2 (pt) * | 2018-07-25 | 2021-04-27 | Innovent Biologics (Suzhou) Co., Ltd. | anticorpo anti-tigit e uso do mesmo |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| CA3109702A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| BR112021003156A2 (pt) | 2018-08-23 | 2021-05-11 | Seagen, Inc. | composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit. |
| CN113039201A (zh) * | 2018-09-28 | 2021-06-25 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD137结合分子及其治疗用途 |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| CR20210239A (es) | 2018-10-12 | 2021-12-15 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas |
| CN113056482A (zh) | 2018-10-18 | 2021-06-29 | 默沙东公司 | 抗rsv抗体的制剂及其使用方法 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| AU2019375409A1 (en) * | 2018-11-05 | 2021-05-27 | Merck Sharp & Dohme Llc | Dosing regimen of anti-TIGIT antibody for treatment of cancer |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| CN111196852A (zh) * | 2018-11-16 | 2020-05-26 | 四川科伦博泰生物医药股份有限公司 | 抗tigit抗体及其用途 |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| KR20210113282A (ko) | 2019-01-07 | 2021-09-15 | 아이테오스 벨지움 에스에이 | 항-tigit 항체 |
| EP3914622A1 (en) * | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| SG11202108398YA (en) * | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
| BR112021015479A2 (pt) * | 2019-02-06 | 2021-12-28 | Pionyr Immunotherapeutics Inc | Anticorpos anti-trem1 e métodos relacionados |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN109833480B (zh) * | 2019-03-22 | 2021-09-07 | 中国科学院上海巴斯德研究所 | 靶向nk细胞免疫检查点治疗感染性疾病的方法 |
| CN111744013B (zh) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
| WO2020216348A1 (en) * | 2019-04-26 | 2020-10-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
| TWI760751B (zh) | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| CN114174537A (zh) * | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
| KR102332847B1 (ko) * | 2019-06-13 | 2021-12-01 | 주식회사 녹십자 | Tigit에 대한 항체 및 이의 용도 |
| AU2020298324A1 (en) * | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIGIT antibodies |
| EP3990116A1 (en) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| WO2021008523A1 (zh) * | 2019-07-15 | 2021-01-21 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体及其应用 |
| CN112300286A (zh) * | 2019-08-02 | 2021-02-02 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
| GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
| MX2022003204A (es) * | 2019-09-19 | 2022-04-18 | Bristol Myers Squibb Co | Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido. |
| JP7122354B2 (ja) * | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | 抗ｔｉｇｉｔ抗体および使用方法 |
| US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
| WO2021067863A2 (en) | 2019-10-03 | 2021-04-08 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| EP4041392A1 (en) * | 2019-10-08 | 2022-08-17 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN113416258B (zh) * | 2019-10-24 | 2023-08-29 | 北京免疫方舟医药科技有限公司 | 一种多特异性抗体及其制备方法和用途 |
| WO2021092196A1 (en) * | 2019-11-05 | 2021-05-14 | Merck Patent Gmbh | Anti-tigit antibodies and uses thereof |
| TW202124452A (zh) * | 2019-11-14 | 2021-07-01 | 中國大陸商上海藥明生物技術有限公司 | 抗tigit的新型抗體 |
| BR112022010069A2 (pt) * | 2019-11-25 | 2022-09-06 | Akeso Biopharma Inc | Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica |
| US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| AU2021205565B2 (en) * | 2020-01-10 | 2026-05-07 | Shanghai Henlius Biotech, Inc. | Anti-TIGIT antibodies, multispecific antibodies comprising the same and methods of using the same |
| CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
| EP4094777A4 (en) * | 2020-01-21 | 2024-01-24 | Innovent Biologics (Suzhou) Co., Ltd. | RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| CN115335406B (zh) | 2020-02-12 | 2026-01-30 | 伊莱利利公司 | 抗体或抗原-结合片段的结晶 |
| US20230092707A1 (en) * | 2020-03-05 | 2023-03-23 | Merck Sharp & Dohme Llc | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody |
| KR20220154140A (ko) | 2020-03-13 | 2022-11-21 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pvrig 결합 단백질 및 이의 의학적 용도 |
| CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN114507284B (zh) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| WO2021238932A1 (zh) * | 2020-05-26 | 2021-12-02 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| US11820824B2 (en) | 2020-06-02 | 2023-11-21 | Arcus Biosciences, Inc. | Antibodies to TIGIT |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| US20230272359A1 (en) * | 2020-07-20 | 2023-08-31 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treatment and prevention of coronavirus infection |
| CA3190660A1 (en) | 2020-08-31 | 2022-03-03 | George C. Lee | Cell localization signature and immunotherapy |
| TWI894360B (zh) * | 2020-09-22 | 2025-08-21 | 大陸商南京聖和藥業股份有限公司 | 抗tigit抗體及雙抗體和它們的應用 |
| WO2022069940A1 (en) | 2020-09-30 | 2022-04-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| AU2021372706A1 (en) * | 2020-10-26 | 2023-06-08 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| JP2023548538A (ja) | 2020-11-08 | 2023-11-17 | シージェン インコーポレイテッド | 併用療法 |
| US11028172B1 (en) * | 2020-11-10 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Anti-TIGIT antibodies and uses thereof |
| EP4238991A4 (en) * | 2020-11-23 | 2024-05-15 | Guangdong Fapon Biopharma Inc. | ANTI-TIGIT ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022111612A1 (zh) * | 2020-11-26 | 2022-06-02 | 信达生物制药(苏州)有限公司 | 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途 |
| CN114539418A (zh) * | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | 双特异性抗体及其用途 |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CN112538108B (zh) * | 2020-12-24 | 2022-06-28 | 郑州大学 | 高亲和pvr突变体 |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| CN116897202A (zh) * | 2021-02-24 | 2023-10-17 | 科济生物医药（上海）有限公司 | Tigit工程化细胞及其组合物 |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2022217026A1 (en) | 2021-04-09 | 2022-10-13 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| AU2022272586A1 (en) * | 2021-05-10 | 2024-01-04 | Medimabbio Inc. | Anti-tigit antibodies and use thereof |
| CN115466327B (zh) * | 2021-06-10 | 2025-07-08 | 北京天广实生物技术股份有限公司 | 结合tigit的抗体及其用途 |
| CN116059341A (zh) * | 2021-07-23 | 2023-05-05 | 中山康方生物医药有限公司 | 药物组合物及用途 |
| TW202320848A (zh) | 2021-07-28 | 2023-06-01 | 美商建南德克公司 | 治療癌症之方法及組成物 |
| CA3229166A1 (en) * | 2021-08-20 | 2023-02-23 | Zhongmin Wang | Fusion protein containing anti-tigit antibody and tgf-?r, and pharmaceutical composition and use thereof |
| CN117940453A (zh) | 2021-09-15 | 2024-04-26 | 江苏恒瑞医药股份有限公司 | 特异性结合pd-1的蛋白及其医药用途 |
| JP2024535768A (ja) | 2021-09-15 | 2024-10-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｐｖｒｉｇ／ｔｉｇｉｔ二重特異性抗体を含む医薬組成物 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023064958A1 (en) | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
| CN118541389A (zh) * | 2021-11-10 | 2024-08-23 | 尖端免疫生医公司 | 抗tigit构建体及其用途 |
| WO2023108609A1 (en) * | 2021-12-17 | 2023-06-22 | Shanghai Nigene Biological Science And Technology Co., Ltd. | Tigit antibodies and uses thereof |
| WO2023149978A1 (en) * | 2022-02-04 | 2023-08-10 | Mereo Biopharma 5, Inc. | Cancer biomarkers and cancer treatments |
| JP2025508076A (ja) | 2022-03-08 | 2025-03-21 | アレンティス・セラピューティクス・アクチェンゲゼルシャフト | Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用 |
| AU2023236289A1 (en) | 2022-03-15 | 2024-08-15 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| CN119562830A (zh) | 2022-06-02 | 2025-03-04 | 百时美施贵宝公司 | 抗体组合物及其使用方法 |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024026496A1 (en) | 2022-07-28 | 2024-02-01 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| CN116143923B (zh) * | 2022-12-30 | 2025-11-11 | 合肥天港免疫药物有限公司 | 高亲和力tigit抗体及其应用 |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| WO2024191807A1 (en) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
| JP2026510747A (ja) | 2023-03-15 | 2026-04-10 | シャンハイ マブジェン バイオテック リミテッド | Ｐｄ－１／ｐｖｒｉｇ／ｔｉｇｉｔ結合タンパク質を含む医薬組成物及びその医薬的使用 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| CN118725130A (zh) * | 2023-03-21 | 2024-10-01 | 上海赛金生物医药有限公司 | 抗ctla-4/抗tigit双特异性抗体及其应用 |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024249894A2 (en) * | 2023-06-02 | 2024-12-05 | Arcus Biosciences, Inc. | Biomarkers for predicting cancer treatment efficacy |
| EP4724493A1 (en) * | 2023-06-06 | 2026-04-15 | WuXi Biologics Ireland Limited | Anti-tigit antibodies and uses thereof |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| CN121219319A (zh) * | 2023-06-27 | 2025-12-26 | 正大天晴药业集团股份有限公司 | 抗tigit抗体及其应用 |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025159595A1 (ko) * | 2024-01-24 | 2025-07-31 | 메디맵바이오 주식회사 | Tigit에 특이적으로 결합하는 항-tigit 항체, 상기 항체 및 인터루킨-10를 포함하는 융합 단백질 및 이들의 용도 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| HRP20130077A2 (hr) | 1998-12-23 | 2013-07-31 | Pfizer Inc. | Humana monoklonalna protutjela za ctla-4 |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| DE60037896D1 (de) | 1999-07-29 | 2008-03-13 | Medarex Inc | Menschliche antikörper gegen her2/neu |
| MXPA02001878A (es) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Moleculas b7-4 novedosas y usos de las mismas. |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| EP1234031B2 (en) | 1999-11-30 | 2021-11-24 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| EP2277532A1 (en) | 2002-09-11 | 2011-01-26 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| WO2004035752A2 (en) | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1706424B1 (en) | 2004-01-12 | 2009-07-22 | Applied Molecular Evolution, Inc. | Fc region variants |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EA010654B1 (ru) | 2004-11-23 | 2008-10-30 | Пи Ай Пи Ко., Лтд. | Вмонтированная в стену распределительная коробка водоснабжения |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| PL2559690T3 (pl) | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| JP2008544746A (ja) | 2005-05-12 | 2008-12-11 | ザイモジェネティクス， インコーポレイテッド | 免疫応答を調節するための組成物および方法 |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US20080206246A1 (en) | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| TWI382974B (zh) | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| KR100897938B1 (ko) | 2007-05-30 | 2009-05-18 | 주식회사 제넥신 | 면역글로불린 융합 단백질 |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| DE102007036200A1 (de) | 2007-08-02 | 2009-02-05 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| SI2195017T1 (sl) | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
| AU2008345242B2 (en) | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| AR069903A1 (es) | 2007-11-30 | 2010-03-03 | Medarex Inc | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer |
| WO2009079242A2 (en) | 2007-12-05 | 2009-06-25 | Massachusetts Institute Of Technology | Aglycosylated immunoglobulin mutants |
| SG10201408158SA (en) | 2008-01-03 | 2015-03-30 | Univ Aix Marseille | Composition and methods used during anti-hiv treatment |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP3208612B1 (en) * | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CN102089325A (zh) | 2008-04-17 | 2011-06-08 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽 |
| CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20100189727A1 (en) | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN108530543B (zh) | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| DK2509409T3 (en) | 2009-12-10 | 2016-11-14 | Regeneron Pharma | MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| HRP20151188T4 (hr) | 2010-02-08 | 2021-10-01 | Regeneron Pharmaceuticals, Inc. | Miš sa zajedničkim lakim lancem |
| PL3053932T3 (pl) | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| US8822642B2 (en) | 2010-06-09 | 2014-09-02 | Zymogenetics, Inc. | Dimeric fusion proteins and related compositions and methods |
| SI2480675T1 (sl) | 2010-06-22 | 2016-08-31 | Regeneron Pharmaceuticals, Inc. | Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CA2824278C (en) | 2010-12-20 | 2022-09-20 | The Rockefeller University | Modulating agonistic tnfr antibodies |
| CA2827923C (en) | 2011-02-25 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc antibody |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US20130149300A1 (en) | 2011-09-27 | 2013-06-13 | Icon Genetics Gmbh | MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104010659A (zh) | 2011-12-19 | 2014-08-27 | 洛克菲勒大学 | 非唾液酸化的抗炎多肽 |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2831245A1 (en) * | 2012-03-28 | 2015-02-04 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| HUE043482T2 (hu) | 2012-09-13 | 2019-08-28 | Bristol Myers Squibb Co | Miosztatint megkötõ fibronektin alapú váz domén proteinek |
| EP2925350B1 (en) * | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| AU2013355379B2 (en) | 2012-12-04 | 2018-08-09 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| CA2921774C (en) | 2013-08-22 | 2023-01-10 | The Council Of The Queensland Institute Of Medical Research | Immunoreceptor modulation for treating cancer and viral infections |
| EP3119913B1 (en) | 2014-03-21 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| PE20170140A1 (es) | 2014-07-16 | 2017-03-30 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer |
| CR20170060A (es) | 2014-08-19 | 2017-04-18 | Merck Sharp & Dohme | Anticuerpos anti tigit |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| PH12022553648A1 (en) | 2015-09-25 | 2024-03-11 | Genentech Inc | Anti-tigit antibodies and methods of use |
-
2015
- 2015-12-22 MY MYPI2017702296A patent/MY187045A/en unknown
- 2015-12-22 EA EA201791171A patent/EA039219B1/ru unknown
- 2015-12-22 AR ARP150104279A patent/AR103268A1/es not_active Application Discontinuation
- 2015-12-22 WO PCT/US2015/067332 patent/WO2016106302A1/en not_active Ceased
- 2015-12-22 EP EP23170440.4A patent/EP4249066A3/en active Pending
- 2015-12-22 AU AU2015369683A patent/AU2015369683C1/en not_active Ceased
- 2015-12-22 TW TW104143215A patent/TWI708786B/zh not_active IP Right Cessation
- 2015-12-22 SG SG11201705063VA patent/SG11201705063VA/en unknown
- 2015-12-22 CN CN201580070988.1A patent/CN107207594B/zh active Active
- 2015-12-22 KR KR1020177020134A patent/KR102644115B1/ko active Active
- 2015-12-22 BR BR112017013385A patent/BR112017013385A2/pt active Search and Examination
- 2015-12-22 UY UY0001036471A patent/UY36471A/es not_active Application Discontinuation
- 2015-12-22 PH PH1/2022/550771A patent/PH12022550771A1/en unknown
- 2015-12-22 SG SG10202006538TA patent/SG10202006538TA/en unknown
- 2015-12-22 CN CN201910247168.5A patent/CN110256558B/zh active Active
- 2015-12-22 EP EP15823895.6A patent/EP3237448A1/en not_active Withdrawn
- 2015-12-22 MA MA40662A patent/MA40662B1/fr unknown
- 2015-12-22 US US14/977,789 patent/US10189902B2/en active Active
- 2015-12-22 MX MX2017007744A patent/MX389267B/es unknown
- 2015-12-22 TN TN2017000267A patent/TN2017000267A1/en unknown
- 2015-12-22 JP JP2016564332A patent/JP6180663B2/ja active Active
- 2015-12-22 CN CN202310623703.9A patent/CN116731176A/zh active Pending
- 2015-12-22 PE PE2017001141A patent/PE20171244A1/es active IP Right Grant
-
2017
- 2017-06-13 MX MX2021012074A patent/MX2021012074A/es unknown
- 2017-06-19 IL IL253013A patent/IL253013B/en unknown
- 2017-06-21 PH PH12017501166A patent/PH12017501166A1/en unknown
- 2017-06-22 CL CL2017001660A patent/CL2017001660A1/es unknown
- 2017-07-12 CO CONC2017/0006989A patent/CO2017006989A2/es unknown
- 2017-07-18 JP JP2017138861A patent/JP6633032B2/ja active Active
- 2017-07-21 ZA ZA2017/04981A patent/ZA201704981B/en unknown
-
2018
- 2018-09-20 ZA ZA2018/06307A patent/ZA201806307B/en unknown
- 2018-12-20 US US16/228,095 patent/US11008390B2/en active Active
-
2019
- 2019-12-11 JP JP2019223659A patent/JP2020062026A/ja active Pending
-
2021
- 2021-02-25 AU AU2021201231A patent/AU2021201231B2/en not_active Ceased
- 2021-04-12 US US17/227,642 patent/US12060421B2/en active Active
- 2021-06-21 JP JP2021102155A patent/JP2021177759A/ja active Pending
- 2021-08-01 IL IL285287A patent/IL285287B2/en unknown
-
2023
- 2023-07-06 JP JP2023111614A patent/JP2023139046A/ja active Pending
-
2025
- 2025-05-27 JP JP2025087824A patent/JP2025128184A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501166B1 (en) | Antibodies to tigit | |
| MX2020010530A (es) | Anticuerpos humanizados contra cd269 (bcma). | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
| MX2019005426A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| EA201891966A1 (ru) | Молекулы, связывающие bcma, и способы их применения | |
| PH12016501384A1 (en) | Human antibodies to pd-l1 | |
| PH12017502129A1 (en) | Antibodies against ox40 and uses thereof | |
| MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX2018007406A (es) | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. | |
| EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
| MX2021003436A (es) | Anticuerpos humanos para pd-1. | |
| MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
| PH12019500571A1 (en) | Anti-pd-1 antibodies | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| TW201613971A (en) | Anti-epidermal growth factor receptor (EGFR) antibodies |